Connell et al. [22] reported that patients treated with neoadjuvant chemotherapy followed by chemoradiotherapy who had high levels of RAD51 protein had worse 2-year survival specific to head and neck cancer (33.3% versus 88.9%, respectively; p = 0.025). Here, RAD51 is linked to head and neck cancer.